Hetlioz is owned by Vanda Pharms Inc.

Hetlioz contains Tasimelteon.

Hetlioz has a total of 22 drug patents out of which 1 drug patent has expired.

Expired drug patents of Hetlioz are:

• US5856529

Hetlioz was authorised for market use on 31 January, 2014.

Hetlioz is available in capsule;oral dosage forms.

Hetlioz can be used as treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food, treatment of non-24 hour sleep-wake disorder by administering tasimelteon, treatment of non-24-hour sleep-wake disorder, treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon, treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor, treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists, treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food, treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine, treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with rifampin; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin, treatment of non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors, treatment of non-24 hour sleep-wake disorder by administering tasimelteon; treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon, treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; treatment of non-24 hour sleep-wake disorder by administering tasimelteon to patients with a smoking history.

The generics of Hetlioz are possible to be released after 29 August, 2035.